Recently, the State Drug Administration approved the launch of the Traditional Chinese Medicine Class 1.1 Innovative Herbal Pepper Seven Pain Relief Gel Patch declared by Hunan Jiudian Pharmaceutical Co., Ltd. This medicine is a traditional Chinese medicine compound for external use. It has the effects of warming and relieving the cold, activating blood circulation and pain relief, and is used for knee osteoarthritis, cold, coagulation, and blood stasis. Recently, the State Drug Administration approved the listing of the Class 1 innovative drug istevir hydrochloride tablets declared by Xihu Pharmaceutical Co., Ltd. with conditions. This drug is an oral small-molecule drug for treating COVID-19 infection and is used to treat light and medium-sized novel coronavirus infections in adults. Recently, the State Drug Administration approved the listing of suldi insulin injections declared by Jiangsu Hengrui Pharmaceutical Co., Ltd. to treat type 2 diabetes in adults. Recently, the State Drug Administration approved the launch of the resicibizumab injection declared by Shanghai Huaotai Biopharmaceutical Co., Ltd. through a priority review and approval procedure to treat generalized pustular psoriatic attacks in adults.

Recently, the State Drug Administration approved the launch of the Traditional Chinese Medicine Class 1.1 Innovative Herbal Pepper Seven Pain Relief Gel Patch declared by Hunan Jiudian Pharmaceutical Co., Ltd. This medicine is a traditional Chinese medicine compound for external use. It has the effects of warming and relieving the cold, activating blood circulation and pain relief, and is used for knee osteoarthritis, cold, coagulation, and blood stasis. Recently, the State Drug Administration approved the listing of the Class 1 innovative drug istevir hydrochloride tablets declared by Xihu Pharmaceutical Co., Ltd. with conditions. This drug is an oral small-molecule drug for treating COVID-19 infection and is used to treat light and medium-sized novel coronavirus infections in adults. Recently, the State Drug Administration approved the listing of suldi insulin injections declared by Jiangsu Hengrui Pharmaceutical Co., Ltd. to treat type 2 diabetes in adults. Recently, the State Drug Administration approved the launch of the resicibizumab injection declared by Shanghai Huaotai Biopharmaceutical Co., Ltd. through a priority review and approval procedure to treat generalized pustular psoriatic attacks in adults.